Abbott Earns FDA Ad Division Letter For Newborn Surfactant Survanta Promotion
This article was originally published in The Pink Sheet Daily
Ad division charges Abbott's Ross Products with unsubstantiated effectiveness claims in a professional mailer for beractant for respiratory distress in premature infants. The letter also takes issue with presentation of risk information.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.